Health Care Stocks Technical Review -- Agenus, Esperion Therapeutics, BioScrip, Affymetrix and Alnylam Pharmaceuticals

NEW YORK, September 24, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on the following equities: Agenus Inc.  (NASDAQ: AGEN), Esperion Therapeutics, Inc. (NASDAQ: ESPR), BioScrip, Inc. (NASDAQ: BIOS), Affymetrix, Inc. (NASDAQ: AFFX), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). On Tuesday, September 22, 2015, Nasdaq ended at 4,756.72, down 1.50%, Dow Jones declined 1.09%, to finish the day at 16,330.47, and the S&P closed at 1,942.74, down 1.23%. Register for your complimentary reports at the links given below.      

--

Agenus Inc 

--

Agenus Inc's stock edged lower by 0.17% to close Wednesday's session at USD 5.99. The company's shares oscillated between USD 5.77 and USD 6.15. The stock recorded a trading volume of 1.03 million shares, which was below its 50-day daily average volume of 1.15 million shares and below its 52-week average volume of 1.42 million shares. Over the last three days, Agenus Inc's shares have declined by 8.41% and in the past one week it has moved down 7.85%. Furthermore, over the last three months, the stock has lost 29.36% and in the past six months, the shares have picked up 22.24%. The stock is trading at a price to book ratio of 9.16 against the historical PB ratio of 10.82. Sign up and read the free notes on AGEN at:  http://www.aciassociation.com/AGEN.pdf  

--

Esperion Therapeutics Inc 

--

The stock of Esperion Therapeutics Inc gained 3.34% to close Wednesday's session at USD 45.42. The shares of the company moved in the range of USD 43.97 and USD 47.24. A trading volume of 1.00 million shares was recorded, which was lower than its 150-day daily average volume of 1.11 million shares and above its 52-week average volume of 0.81 million shares. Over the last five days, Esperion Therapeutics Inc's shares have declined by 0.81% and in the past one month, it has lost 16.61%. Additionally, over the last three months, the stock has declined 45.94% and in the past six months, the shares have registered a loss of 47.93%. Register for free on ACI Association and access the latest research on ESPR at:  http://www.aciassociation.com/ESPR.pdf

--

BioScrip Inc 

--

BioScrip Inc's stock decreased 7.29% to close Wednesday's session at USD 2.67. The company's shares fluctuated in the range of USD 2.64 and USD 2.90. A total of 0.96 million shares exchanged hands, which was lesser than its 50-day daily average volume of 1.27 million shares and was below its 52-week average volume of 1.22 million shares. Over the last three days, BioScrip Inc's shares have declined by 9.49%, over the last three months, the stock has lost 26.45% and in the past six months, the shares have shed 38.34%. Additionally, the stock is trading at a price to sales ratio of 0.18. The complete research on BIOS is available for free at: http://www.aciassociation.com/BIOS.pdf

--

Affymetrix Inc 

--

Affymetrix Inc's stock added 1.24% to close Wednesday's session at USD 9.01. The company's shares oscillated between USD 8.89 and USD 9.12. The stock recorded a trading volume of 0.94 million shares, which was above its 50-day daily average volume of 0.65 million shares and above its 52-week average volume of 0.85 million shares. Over the last five days, Affymetrix Inc's shares have declined by 4.96% and in the past one month, it has lost 4.15%. In addition, over the last three months, the stock has lost 21.92% and year to date, the shares have shed 8.71%. Further, the company is trading at a price to earnings ratio of 40.95 and a price to book ratio of 2.14. Free in-depth research on AFFX is available at:  http://www.aciassociation.com/AFFX.pdf

--

Alnylam Pharmaceuticals Inc 

--

Alnylam Pharmaceuticals Inc's stock declined 4.12% to close Wednesday's session at USD 93.30. The share price vacillated between USD 92.22 and USD 97.55. The stock recorded a trading volume of 0.93 million shares, which was above its 50-day daily average volume of 0.75 million shares and above its 52-week average volume of 0.75 million shares. Over the last three days, Alnylam Pharmaceuticals Inc's shares have declined by 13.49% and in the past one week, it has moved down 12.68%. Moreover, in the last six months, the stock has lost 8.33% and year to date, the shares have shed 3.81%. The stock is trading at a price to book ratio of 5.60 against the historical PB ratio of 8.00. The complimentary notes on ALNY can be downloaded in PDF format at:  http://www.aciassociation.com/ALNY.pdf

--

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY 

ACI Association, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.

RESTRICTIONS 

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.aciassociation.com